News

BioSig Technologies, Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced that the...

Cardiva Medical®, an innovator in the field of vascular closure, announced that the company has closed on $11 million in additional financing – bringing total equity and debt financing in the current round to $41 million. The additional...

Catheter Precision Inc. announced the initiation of a pivotal clinical trial to assess the accuracy and safety of the VIVO™ (View Into Ventricular Onset) Non-Invasive Mapping System. The VIVO system is designed to provide pre-procedure...

The International Board of Heart Rhythm Examiners (IBHRE) announced activities for its annual IBHRE Day celebration—Monday, Feb. 12. This global day of recognition acknowledges and celebrates physicians, nurses and other allied professionals...

Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), announces it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects...

AnaBios announced a partnership with Sanofi to develop a new treatment for atrial fibrillation. The program will focus on compounds designed to modulate a novel cardiac ion channel target. Through this agreement, AnaBios will acquire...

Confluent Medical Technologies, a global leader in medical device contract manufacturing, completed the acquisition of Corpus Medical. Confluent Medical is a contract manufacturer with full-scale capabilities to provide high-quality, low-cost...

Syneos Health Communications released a report that provides pioneering perspectives into patients’ thought processes as they confront a future with artificial intelligence (AI). The first of its kind research reveals that excitement over...

The CASTLE-AF study—described as “potentially guideline-changing”, has been published in the New England Journal of Medicine .1 The trial, conducted with BIOTRONIK’s support, shows a 38 percent reduction in the composite endpoint of...

Boehringer Ingelheim announced results from a retrospective, observational real-world study assessing the safety and effectiveness of novel oral anticoagulants (NOACs) among patients with non-valvular atrial fibrillation (NVAF) treated...